ANTX insider transaction filings
AN2 Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-16. Screen ANTX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 11 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 2,098 shares, $11,602 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 5 filings by 3 insiders — 58,846 shares, $343,007 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
- Largest priced transaction: sale of 18,706 shares @ $6.01 ($112,389) by Readnour Robin Shane, filed 2026-08-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Readnour Robin Shane — Director | 3 | — | 8 legs · 52,629 sh · $316,700 | — |
| Eizen Joshua M — See Remarks | 1 | — | 1 leg · 5,945 sh · $24,803 | — |
| FitzPatrick Margaret M — Director | 1 | 1 leg · 2,098 sh · $11,602 | — | — |
| Williams Sarah Joanne — Principal Accounting Officer | 1 | — | 1 leg · 272 sh · $1,504 | — |
| Trenor Cameron C. III — Chief Medical Officer | 1 | — | — | 2 |
| Aziz Kabeer — Director | 1 | — | — | 1 |
| Marks Gilbert Lynn — Director | 1 | — | — | 1 |
| Martin Patricia A. — Director | 1 | — | — | 1 |
| Zakrzewski Joseph S — Director | 1 | — | — | 1 |
Recent Form 4 filings — AN2 Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | Trenor Cameron C. III — Chief Medical Officer | Grant/award (A): 116,667 @ $0 · Grant/award (A): 233,333 (derivative) @ $0 | EDGAR |
| 2026-09-11 | 4 | Readnour Robin Shane — Director | Sale (S): 523 @ $6.02 · Sale (S): 585 @ $6.02 | EDGAR |
| 2026-09-08 | 4 | Readnour Robin Shane — Director | Sale (S): 2,877 @ $6.07 · Sale (S): 3,223 @ $6.07 · Sale (S): 4,725 @ $6.02 · Sale (S): 5,294 @ $6.02 | EDGAR |
| 2026-09-04 | 4 | Williams Sarah Joanne — Principal Accounting Officer | Sale (S): 272 @ $5.53 | EDGAR |
| 2026-09-02 | 4 | FitzPatrick Margaret M — Director | Purchase (P): 2,098 @ $5.53 | EDGAR |
| 2026-08-19 | 4 | Readnour Robin Shane — Director | Sale (S): 16,696 @ $6.01 · Sale (S): 18,706 @ $6.01 | EDGAR |
| 2026-08-14 | 4 | Zakrzewski Joseph S — Director | Gift (G): 405,880 @ $0 | EDGAR |
| 2026-07-10 | 4 | Aziz Kabeer — Director | Grant/award (A): 2,852 @ $0 | EDGAR |
| 2026-07-10 | 4 | Marks Gilbert Lynn — Director | Grant/award (A): 2,789 @ $0 | EDGAR |
| 2026-07-10 | 4 | Martin Patricia A. — Director | Grant/award (A): 766 @ $0 | EDGAR |
| 2026-07-10 | 4 | Eizen Joshua M — See Remarks | Sale (S): 5,945 @ $4.17 | EDGAR |
| 2026-06-02 | 4 | Williams Sarah Joanne — Principal Accounting Officer | Sale (S): 265 @ $4.43 | EDGAR |
| 2026-04-10 | 4 | Aziz Kabeer — Director | Grant/award (A): 3,775 @ $0 | EDGAR |
| 2026-04-10 | 4 | Marks Gilbert Lynn — Director | Grant/award (A): 3,775 @ $0 | EDGAR |
| 2026-04-10 | 4 | Martin Patricia A. — Director | Grant/award (A): 1,192 @ $0 | EDGAR |
| 2026-03-23 | 4 | Day Lucy — Chief Financial Officer | Grant/award (A): 73,665 (derivative) · Disposition to issuer (D): 73,665 (derivative) · Grant/award (A): 66,000 (derivative) · Disposition to issuer (D): 66,000 (derivative) · Grant/award (A): 82,300 (derivative) · Disposition to issuer (D): 82,300 (derivative) | EDGAR |
| 2026-03-23 | 4 | Marks Gilbert Lynn — Director | Grant/award (A): 10,665 (derivative) · Disposition to issuer (D): 10,665 (derivative) · Grant/award (A): 10,362 (derivative) · Disposition to issuer (D): 10,362 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-03-23 | 4 | Aziz Kabeer — Director | Grant/award (A): 20,724 (derivative) · Disposition to issuer (D): 20,724 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-03-23 | 4 | Martin Patricia A. — Director | Grant/award (A): 24,999 (derivative) · Disposition to issuer (D): 24,999 (derivative) · Grant/award (A): 10,362 (derivative) · Disposition to issuer (D): 10,362 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-03-23 | 4 | Eizen Joshua M — See Remarks | Grant/award (A): 92,000 (derivative) · Disposition to issuer (D): 92,000 (derivative) · Grant/award (A): 50,150 (derivative) · Disposition to issuer (D): 50,150 (derivative) | EDGAR |
| 2026-03-23 | 4 | Readnour Robin Shane — Director | Grant/award (A): 20,724 (derivative) · Disposition to issuer (D): 20,724 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-03-23 | 4 | Easom Eric — Chief Executive Officer, Director | Grant/award (A): 249,999 (derivative) · Disposition to issuer (D): 249,999 (derivative) · Grant/award (A): 225,000 (derivative) · Disposition to issuer (D): 225,000 (derivative) · Grant/award (A): 267,650 (derivative) · Disposition to issuer (D): 267,650 (derivative) | EDGAR |
| 2026-03-23 | 4 | FitzPatrick Margaret M — Director | Grant/award (A): 11,463 (derivative) · Disposition to issuer (D): 11,463 (derivative) · Grant/award (A): 10,362 (derivative) · Disposition to issuer (D): 10,362 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-03-23 | 4 | Chanda Sanjay — Chief Development Officer | Grant/award (A): 66,000 (derivative) · Disposition to issuer (D): 66,000 (derivative) · Grant/award (A): 57,950 (derivative) · Disposition to issuer (D): 57,950 (derivative) · Grant/award (A): 41,665 (derivative) · Disposition to issuer (D): 41,665 (derivative) | EDGAR |
| 2026-03-23 | 4 | Wong Stephanie — Director | Grant/award (A): 24,999 (derivative) · Disposition to issuer (D): 24,999 (derivative) · Grant/award (A): 10,362 (derivative) · Disposition to issuer (D): 10,362 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-03-23 | 4 | Spigelman Melvin K — Director | Grant/award (A): 16,941 (derivative) · Disposition to issuer (D): 16,941 (derivative) · Grant/award (A): 10,362 (derivative) · Disposition to issuer (D): 10,362 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-03-23 | 4 | Zakrzewski Joseph S — Director | Grant/award (A): 99,999 (derivative) · Disposition to issuer (D): 99,999 (derivative) · Grant/award (A): 10,362 (derivative) · Disposition to issuer (D): 10,362 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-03-05 | 4 | Williams Sarah Joanne — Principal Accounting Officer | Sale (S): 327 @ $1.06 | EDGAR |
| 2026-02-23 | 4 | Eizen Joshua M — See Remarks | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Day Lucy — Chief Financial Officer | Grant/award (A): 38,000 @ $0 · Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Williams Sarah Joanne — Principal Accounting Officer | Grant/award (A): 48,375 @ $0 | EDGAR |
| 2026-02-23 | 4 | Easom Eric — Chief Executive Officer, Director | Grant/award (A): 112,250 @ $0 · Grant/award (A): 224,500 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Marks Gilbert Lynn — Director | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Readnour Robin Shane — Director | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Martin Patricia A. — Director | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Aziz Kabeer — Director | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | FitzPatrick Margaret M — Director | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Chanda Sanjay — Chief Development Officer | Grant/award (A): 38,000 @ $0 · Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Wong Stephanie — Director | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Spigelman Melvin K — Director | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Zakrzewski Joseph S — Director | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Aziz Kabeer — Director | Grant/award (A): 11,560 @ $0 | EDGAR |
| 2026-01-14 | 4 | Martin Patricia A. — Director | Grant/award (A): 3,650 @ $0 | EDGAR |
| 2026-01-14 | 4 | Marks Gilbert Lynn — Director | Grant/award (A): 11,560 @ $0 | EDGAR |
| 2026-01-07 | 4 | Day Lucy — Chief Financial Officer | Sale (S): 3,295 @ $1.00 · Sale (S): 5,512 @ $1.01 | EDGAR |
| 2026-01-07 | 4 | Prior Stephen David — Chief Strategy Officer | Sale (S): 3,604 @ $1.00 · Sale (S): 2,858 @ $1.01 | EDGAR |
| 2026-01-07 | 4 | Eizen Joshua M — See Remarks | Sale (S): 17,923 @ $1.00 · Sale (S): 6,931 @ $1.01 | EDGAR |
| 2026-01-07 | 4 | Chanda Sanjay — Chief Development Officer | Sale (S): 3,295 @ $1.00 · Sale (S): 5,956 @ $1.01 | EDGAR |
| 2025-11-06 | 4 | Eizen Joshua M — See Remarks | Sale (S): 2,819 @ $1.14 | EDGAR |
| 2025-11-06 | 4 | Prior Stephen David — Chief Strategy Officer | Sale (S): 765 @ $1.14 | EDGAR |
Recent 8-K events — AN2 Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ANTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →